Highly synergistic opportunities create significant shareholder value creation. The transaction is expected to generate substantial synergies on both the top- and bottom-line.The transaction provides Quidel with ample whitespace opportunity to capture demand in emerging markets through telehealth technology and digital health capabilities, utilizing Ortho’s strong customer relationships and providing greater patient access to point-of-care diagnostic products. Balanced and diversified product portfolio across diagnostic instruments and assays. The companies’ highly complementary, world-class product and service offerings provide opportunities to capture significant growth globally while enhancing cross-selling opportunities across a diversified customer and channel mix.With complementary areas of focus, the combined company will also operate with global reach and scale, maintaining the speed and agility that is fundamental to enhance Quidel’s current strategic approach. Further, the combined company will be poised to meet patient testing needs at all points of the care continuum – reference labs, hospitals, physicians’ offices, urgent care centers and at-home / retail locations. The combined organization will unite world-class technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings. We look forward to joining together to continue the strong patient focus that is core to our mission, creating an organization with a shared goal of discovering, developing, and delivering innovative solutions to our customers.” We are impressed by what Ortho has accomplished for patients. Importantly, our complementary cultures are underpinned by a commitment to our customers, patients, and the communities we serve, reinforcing our confidence in the long-term value creation of this transaction. “Establishing a stronger leadership position, we expect the combined company will emerge as a global player with top-tier R&D capabilities, a more diverse product pipeline, and broader geographic footprint. “The combination with Ortho will help solidify Quidel as a leader in the diagnostics industry, bringing together innovative, complementary products, solutions, and services that enhance the health and well-being of patients across the globe,” said Douglas Bryant, President and Chief Executive Officer of Quidel, who will serve as Chairman and Chief Executive Officer of the combined company. The transaction is expected to close during the first half of fiscal year 2022, subject to customary closing conditions. This industry first feature provides near real-time infectious disease mapping and reporting.Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) today announced that they have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world’s largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over Ortho’s closing price on Decemand an equity value of approximately $6.0 billion. With the power of Virena wireless connectivity and, all instrument and user history can be easily, securely and remotely accessed from any desktop. From the small physician office laboratory to larger hospital labs or emergency departments, Sofia's high performance, objectivity, quality control, fail-safe measures, LIS capabilities and expanding test menu make Sofia the perfect solution for those looking to improve their rapid testing algorithm. Sofia rapid test kits are easy to use, which means Sofia can be adapted to the needs of any healthcare setting. Sofia 2 has the power to deliver highly accurate, objective and automated Influenza A+B and RSV results fast. With Sofia 2’s proprietary Advance Result Technology (ART), Sofia 2 can produce and store results in as few as 3 minutes, giving you, your providers and your patients an accurate result, faster than ever before. Proven lateral-flow technology and proprietary advanced fluorescence chemistry and assay development techniques are all integrated into two small bench top analyzers that can be used near patient and in laboratory settings. Sofia, the next generation in diagnostic testing, takes rapid testing to a whole new level.
0 kommentar(er)
